Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease

AIMS: In the COMPASS trial, rivaroxaban 2.5 mg twice daily (bid) plus acetylsalicylic acid (ASA) 100 mg once daily (od) performed better than ASA 100 mg od alone in reducing the rate of cardiovascular disease, stroke, or myocardial infarction (MI) in patients with coronary artery disease (CAD) and p...

Descripción completa

Detalles Bibliográficos
Autores principales: Cowie, Martin R, Lamy, André, Levy, Pierre, Mealing, Stuart, Millier, Aurélie, Mernagh, Paul, Cristeau, Olivier, Bowrin, Kevin, Briere, Jean-Baptiste
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Review Series from the Naples 2019 Joint Meeting of the ESC Working Groups on Myocardial Function and Cellular Biology of the Heart
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449563/
https://www.ncbi.nlm.nih.gov/pubmed/31807773
http://dx.doi.org/10.1093/cvr/cvz278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449563/
https://www.ncbi.nlm.nih.gov/pubmed/31807773
http://dx.doi.org/10.1093/cvr/cvz278

Ejemplares similares